Journal of Surgical Research
Volume 147, Issue 1 , Pages 23-33 , 1 June 2008

Interleukin-6 Mediates G0/G1 Growth Arrest in Hepatocellular Carcinoma Through a STAT 3-Dependent Pathway

  • Dairmuid M. Moran, Ph.D.

      Affiliations

    • Department of Biology, University of North Carolina at Charlotte, Charlotte, North Carolina
    • School of Biotechnology, Dublin City University, Dublin, Ireland
    • ,
  • M. Adrian Mattocks, B.S.

      Affiliations

    • Department of Biology, University of North Carolina at Charlotte, Charlotte, North Carolina
    • ,
  • Paul A. Cahill, Ph.D.

      Affiliations

    • School of Biotechnology, Dublin City University, Dublin, Ireland
    • ,
  • Leonidas G. Koniaris, M.D.

      Affiliations

    • Dewitt Daughtry Department of Surgery, University of Miami School of Medicine, Miami, Florida
    • ,
  • Iain H. McKillop, Ph.D.

      Affiliations

    • Department of Biology, University of North Carolina at Charlotte, Charlotte, North Carolina
    • Corresponding Author InformationTo whom correspondence and reprint requests should be addressed at Department of Biology, University of North Carolina at Charlotte, Charlotte, NC 28223.

Received 19 March 2007

References 

  1. Macdonald GA. Pathogenesis of hepatocellular carcinoma. Clin Liver Dis. 2001;5:69
  2. McKillop IH, Moran DM, Jin X, et al. Molecular pathogenesis of hepatocellular carcinoma. J Surg Res. 2006;136:125
  3. Okuda K. Hepatocellular carcinoma—history, current status and perspectives. Dig Liver Dis. 2002;34:613
  4. Bosch FX, Ribes J, Cleries R, et al. Epidemiology of hepatocellular carcinoma. Clin Liver Dis. 2005;9:191;v
  5. Befeler AS, Di Bisceglie AM. Hepatocellular carcinoma: diagnosis and treatment. Gastroenterology. 2002;122:1609
  6. Koniaris LG, McKillop IH, Schwartz SI, et al. Liver regeneration. J Am Coll Surg. 2003;197:634
  7. Ramadori G, Christ B. Cytokines and the hepatic acute-phase response. Semin Liver Dis. 1999;19:141
  8. Streetz KL, Luedde T, Manns MP, et al. Interleukin 6 and liver regeneration. Gut. 2000;47:309
  9. Yamada Y, Kirillova I, Peschon JJ, et al. Initiation of liver growth by tumor necrosis factor: deficient liver regeneration in mice lacking type I tumor necrosis factor receptor. Proc Natl Acad Sci USA. 1997;94:1441
  10. Heinrich PC, Behrmann I, Haan S, et al. Principles of interleukin (IL)-6-type cytokine signalling and its regulation. Biochem J. 2003;374:1
  11. Fukada T, Hibi M, Yamanaka Y, et al. Two signals are necessary for cell proliferation induced by a cytokine receptor gp130: involvement of STAT3 in anti-apoptosis. Immunity. 1996;5:449
  12. Chang L, Karin M. Mammalian MAP kinase signalling cascades. Nature. 2001;410:37
  13. Moran DM, Mayes N, Koniaris LG, et al. Interleukin-6 inhibits cell proliferation in a rat model of hepatocellular carcinoma. Liver Int. 2005;25:445
  14. Maione D, Di Carlo E, Li W, et al. Coexpression of IL-6 and soluble IL-6R causes nodular regenerative hyperplasia and adenomas of the liver. EMBO J. 1998;17:5588
  15. Schirmacher P, Peters M, Ciliberto G, et al. Hepatocellular hyperplasia, plasmacytoma formation, and extramedullary hematopoiesis in interleukin (IL)-6/soluble IL-6 receptor double-transgenic mice. Am J Pathol. 1998;153:639
  16. Zimmers TA, McKillop IH, Pierce RH, et al. Massive liver growth in mice induced by systemic interleukin 6 administration. Hepatology. 2003;38:326
  17. Chen RH, Chang MC, Su YH, et al. Interleukin-6 inhibits transforming growth factor-beta-induced apoptosis through the phosphatidylinositol 3-kinase/Akt and signal transducers and activators of transcription 3 pathways. J Biol Chem. 1999;274:23013
  18. Kawano M, Hirano T, Matsuda T, et al. Autocrine generation and requirement of BSF-2/IL-6 for human multiple myelomas. Nature. 1988;332:83
  19. Kortylewski M, Heinrich PC, Mackiewicz A, et al. Interleukin-6 and oncostatin M-induced growth inhibition of human A375 melanoma cells is STAT-dependent and involves upregulation of the cyclin-dependent kinase inhibitor p27/Kip1. Oncogene. 1999;18:3742
  20. Miki S, Iwano M, Miki Y, et al. Interleukin-6 (IL-6) functions as an in vitro autocrine growth factor in renal cell carcinomas. FEBS Lett. 1989;250:607
  21. Kumagai N, Tsuchimoto K, Tsunematsu S, et al. Inhibition of growth of human hepatoma cells by dual-function antisense IL-6 oligonucleotides. Hepatol Res. 2002;22:119
  22. Kim H, Baumann H. Dual signaling role of the protein tyrosine phosphatase SHP-2 in regulating expression of acute-phase plasma proteins by interleukin-6 cytokine receptors in hepatic cells. Mol Cell Biol. 1999;19:5326
  23. Klausen P, Pedersen L, Jurlander J, et al. Oncostatin M and interleukin 6 inhibit cell cycle progression by prevention of p27kip1 degradation in HepG2 cells. Oncogene. 2000;19:3675
  24. Moran DM, Koniaris LG, Jablonski EM, et al. Microencapsulation of engineered cells to deliver sustained high circulating levels of interleukin-6 to study hepatocellular carcinoma progression. Cell Transplant. 2006;15:785
  25. Taub R. Liver regeneration: from myth to mechanism. Nat Rev Mol Cell Biol. 2004;5:836
  26. Cressman DE, Greenbaum LE, DeAngelis RA, et al. Liver failure and defective hepatocyte regeneration in interleukin-6-deficient mice. Science. 1996;274:1379
  27. Huynh H, Nguyen TT, Chow KH, et al. Over-expression of the mitogen-activated protein kinase (MAPK) kinase (MEK)-MAPK in hepatocellular carcinoma: its role in tumor progression and apoptosis. BMC Gastroenterol. 2003;3:19
  28. Park HJ, Kim BC, Kim SJ, et al. Role of MAP kinases and their cross-talk in TGF-beta1-induced apoptosis in FaO rat hepatoma cell line. Hepatology. 2002;35:1360
  29. Sengupta TK, Talbot ES, Scherle PA, et al. Rapid inhibition of interleukin-6 signaling and Stat3 activation mediated by mitogen-activated protein kinases. Proc Natl Acad Sci USA. 1998;95:11107
  30. Bravo J, Heath JK. Receptor recognition by gp130 cytokines. EMBO J. 2000;19:2399
  31. Morgan DO. Principles of CDK regulation. Nature. 1995;374:131
  32. Sherr CJ, Roberts JM. CDK inhibitors: positive and negative regulators of G1-phase progression. Genes Dev. 1999;13:1501
  33. Bellido T, O'Brien CA, Roberson PK, et al. Transcriptional activation of the p21(WAF1,CIP1,SDI1) gene by interleukin-6 type cytokines (A prerequisite for their pro-differentiating and anti-apoptotic effects on human osteoblastic cells). J Biol Chem. 1998;273:21137
  34. Ernst M, Inglese M, Waring P, et al. Defective gp130-mediated signal transducer and activator of transcription (STAT) signaling results in degenerative joint disease, gastrointestinal ulceration, and failure of uterine implantation. J Exp Med. 2001;194:189
  35. Sandberg EM, Ma X, VonDerLinden D, et al. Jak2 tyrosine kinase mediates angiotensin II-dependent inactivation of ERK2 via induction of mitogen-activated protein kinase phosphatase 1. J Biol Chem. 2004;279:1956
  36. Banerji L, Glassford J, Lea NC, et al. BCR signals target p27(Kip1) and cyclin D2 via the PI3-K signalling pathway to mediate cell cycle arrest and apoptosis of WEHI 231 B cells. Oncogene. 2001;20:7352
  37. Spiotto MT, Chung TD. STAT3 mediates IL-6-induced growth inhibition in the human prostate cancer cell line LNCaP. Prostate. 2000;42:88
  38. Florenes VA, Lu C, Bhattacharya N, et al. Interleukin-6 dependent induction of the cyclin dependent kinase inhibitor p21WAF1/CIP1 is lost during progression of human malignant melanoma. Oncogene. 1999;18:1023
  39. Lu C, Kerbel RS. Interleukin-6 undergoes transition from paracrine growth inhibitor to autocrine stimulator during human melanoma progression.[erratum appears in J Cell Biol 1993 Apr;121:following 477]. J Cell Biol. 1993;120:1281
  40. Takizawa H, Ohtoshi T, Ohta K, et al. Growth inhibition of human lung cancer cell lines by interleukin 6 in vitro: a possible role in tumor growth via an autocrine mechanism. Cancer Res. 1993;53:4175
  41. Kerbel RS. Expression of multi-cytokine resistance and multi-growth factor independence in advanced stage metastatic cancer (Malignant melanoma as a paradigm). Am J Pathol. 1992;141:519
  42. Lu C, Vickers MF, Kerbel RS. Interleukin 6: a fibroblast-derived growth inhibitor of human melanoma cells from early but not advanced stages of tumor progression. Proc Natl Acad Sci USA. 1992;89:9215

PII: S0022-4804(07)00279-X

doi: 10.1016/j.jss.2007.04.022

Journal of Surgical Research
Volume 147, Issue 1 , Pages 23-33 , 1 June 2008

Article Tools

* Image Usage & Resolution